(Concerto) Study of BLU-451 in Advanced Cancers With EGFR Exon 20 Insertion Mutations

ClinicalTrials.gov ID: NCT05241873

Public ClinicalTrials.gov record NCT05241873. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Oct 22, 2026, 2:33 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Phase I/II Study of BLU-451 in Advanced Cancers With EGFR Exon 20 Insertion Mutations

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This is a Phase 1/2, open-label first-in-human study of the safety, pharmacokinetics (PK), pharmacodynamics, and anti-tumor activity of BLU-451 monotherapy and BLU-451 in combination with platinum-based chemotherapy (carboplatin and pemetrexed). All participants will receive BLU-451 on a 21-day treatment cycle.

Study identification

NCT ID: NCT05241873
Recruitment status: Terminated
Study type: Interventional
Phase: Phase 1
Lead sponsor: Blueprint Medicines Corporation; Industry
Enrollment: 103 participants

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Mar 4, 2022 (Actual)
Primary completion: Jul 31, 2024 (Actual)
Completion: Jul 31, 2024 (Actual)
Last update posted: Feb 10, 2025

2022 – 2024

United States locations

U.S. sites: 13
U.S. states: 10
U.S. cities: 11

Facility	City	State	ZIP	Site status
City of Hope (City of Hope National Medical Center, City of Hope Medical Center)	Duarte	California	91010	—
Cedars-Sinai Medical Center, Samuel Oschin Comprehensive Cancer Institute	Los Angeles	California	90048	—
University of Colorado Hospital - Anschutz Cancer Pavilion (ACP)	Aurora	Colorado	80045	—
Georgetown University Medical Center	Washington D.C.	District of Columbia	20007	—
Northwestern Memorial Hospital	Chicago	Illinois	60611	—
Massachusetts General Hospital	Boston	Massachusetts	02114	—
Dana-Farber Cancer Institute	Boston	Massachusetts	02215	—
Laura & Isaac Perlmutter Cancer Center at NYU Langone Health	New York	New York	10016	—
Memorial Sloan Kettering Cancer Center	New York	New York	10065	—
Hospital of the University of Pennsylvania	Philadelphia	Pennsylvania	19104	—
The University of Texas M.D. Anderson Cancer Center	Houston	Texas	77030-4009	—
New Experimental Therapeutics of Virginia (NEXT Oncology)	Fairfax	Virginia	22031	—
Fred Hutchinson Cancer Center	Seattle	Washington	98109	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 10 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT05241873, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Feb 10, 2025 · Synced Oct 22, 2026

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT05241873 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →